Market News (Page 23) - TendieTensor

Market News Page 23 of 281 • 7,014 articles

Why Is Medtronic Stock Trading Higher After Analyst Upgrade

Benzinga • Vandana Singh

Why Is Medtronic Stock Trading Higher After Analyst Upgrade

01/06/2026 02:38 PM • William Blair upgraded Medtronic (MDT) from Market Perform to Outperform, citing new product launches and ramping growth drivers including the Hugo surgical system, Symplicity Spyral RDN system, and Pulsed Field Ablation platform. The analyst noted the stock trades at a favorable valuation of ~16x 2026 EPS with potential for low-double-digit equity returns including dividend yield. Medtronic shares rose 2.91% following the upgrade.

LLY - Mentioned briefly as part of national efforts to improve medication affordability, with no specific actions detailed
MDT - Upgraded from Market Perform to Outperform by William Blair based on multiple growth catalysts including new product launches (Hugo system, Symplicity Spyral RDN, PFA platform), favorable valuation at 16x 2026 EPS, potential for high-single-digit EPS growth and low-double-digit equity returns, plus improved visibility from CMS reimbursement decisions. Stock price increased 2.91% on the upgrade.

#analyst upgrade #medical devices #product launches #surgical systems #cardiac ablation #diabetes spin-off #valuation #EPS growth

Nike Stock: Insiders Just Bought the Dip, Including Apple’s CEO

Investing.com • Leo Miller

Nike Stock: Insiders Just Bought the Dip, Including Apple’s CEO

01/06/2026 02:35 PM • Nike stock plummeted 10.5% on December 19, 2025, following mixed earnings results. However, insider confidence is building as Apple CEO Tim Cook purchased $2.95 million in Nike shares, independent director Robert Swan bought $500,000 worth, and Nike CEO Elliott Hill acquired over $1 million in shares. These coordinated insider purchases suggest management and board alignment on the company's recovery prospects, with shares rising 13% from their December lows to around $64.50.

NKE - Multiple insider purchases by CEO Elliott Hill, Apple CEO Tim Cook, and independent director Robert Swan signal confidence in Nike's recovery despite recent 10.5% stock decline. The coordinated buying from both management and independent directors suggests alignment on company's path forward. Stock has recovered 13% from lows, and consensus price target implies 18% upside potential.

#insider buying #Nike earnings #Tim Cook #Elliott Hill #stock recovery #independent directors #China performance #margin improvement

atom11 Launches Neo, Award-Winning Amazon Ads Copilot for Amazon Sellers

GlobeNewswire Inc. • Neha Bhuchar

atom11 Launches Neo, Award-Winning Amazon Ads Copilot for Amazon Sellers

01/06/2026 02:00 PM • atom11 has launched Neo, an AI copilot designed to help Amazon sellers and agencies analyze sales fluctuations by integrating Seller Central and advertising data. The tool reduces analysis time by 93% by comparing 15+ performance signals across ads, inventory, pricing, and other retail metrics to provide actionable insights. Neo has won the AI Innovation Award at the Amazon Ads Partner Awards 2025.

AMZN - Amazon's advertising platform and seller ecosystem are being enhanced by third-party tools like Neo, which improves seller efficiency and advertising performance. This indicates a growing, healthy marketplace that attracts innovation and investment.

#AI copilot #Amazon sellers #sales analysis #PPC automation #data integration #performance optimization #Amazon advertising

SUCCESS® January Digital Edition Explores Reinvention as a Lifelong Skill—Not a One-Time Reset

GlobeNewswire Inc. • Not Specified

SUCCESS® January Digital Edition Explores Reinvention as a Lifelong Skill—Not a One-Time Reset

01/06/2026 01:50 PM • SUCCESS® Magazine released its January 2026 digital edition, positioning reinvention as a core professional skill rather than a New Year's resolution. The issue features cover story with Amy Porterfield on strategic scaling, explores midcareer pivots, and provides actionable tools including a reinvention roadmap and goal-tracking system. The edition is available free with SUCCESS Labs™ signup.

IONQ.WS - Promising trapped-ion quantum computing technology, ambitious roadmap to develop quantum systems with up to 2 million physical qubits by 2030, and diversification into quantum networking, sensing, and security solutions
EXPI - SUCCESS® Magazine, a subsidiary of eXp World Holdings, is expanding its digital offerings and content platforms (SUCCESS Labs™, SUCCESS Coaching™, SUCCESS+™) to serve professionals seeking growth and transformation. The launch of free digital content and integrated technology platforms demonstrates business expansion and increased engagement initiatives.

#reinvention #professional development #career pivot #digital strategy #personal transformation #midcareer change #goal setting #leadership

Waters-Becton Dickinson Deal May Deliver Bigger Gains Than Expected: Analyst

Benzinga • Vandana Singh

Waters-Becton Dickinson Deal May Deliver Bigger Gains Than Expected: Analyst

01/06/2026 01:48 PM • William Blair initiated Outperform coverage on Waters Corporation following its merger with Becton Dickinson's Biosciences & Diagnostic Solutions business. The analyst sees greater synergy upside than initially priced in, with EPS accretion of ~$0.10 in 2026 rising to ~$2.70 by 2028. William Blair projects roughly 20% upside by year-end 2026 and believes the $345 million EBITDA synergy target is conservative based on comparable large M&A deals in life sciences.

GOOG - Significant financial resources, notable quantum computing milestones, potential to advance AI efforts, and ability to leverage quantum computing for Google Cloud growth
WAT - Analyst initiated Outperform rating with 20% upside target by year-end 2026. Strong strategic fit with merger partner, significant EPS accretion expected, and analyst believes synergy targets are conservative based on comparable deals.

#merger #M&A #synergies #EPS accretion #analyst coverage #life sciences #quality assurance

JYD FINAL DEADLINE: ROSEN, A HIGHLY RECOGNIZED LAW FIRM, Encourages Jayud Global Logistics Ltd. Investors to Secure Counsel Before Important January 20 Deadline in Securities Class Action - JYD

GlobeNewswire Inc. • Rosen Law Firm

JYD FINAL DEADLINE: ROSEN, A HIGHLY RECOGNIZED LAW FIRM, Encourages Jayud Global Logistics Ltd. Investors to Secure Counsel Before Important January 20 Deadline in Securities Class Action - JYD

01/06/2026 01:45 PM • Rosen Law Firm has issued urgent deadline notices for investors in multiple companies involved in securities class action lawsuits. The firm is reminding investors of Jayud Global Logistics Ltd. to meet the January 20, 2026 lead plaintiff deadline, citing allegations of fraudulent stock promotion schemes and misleading statements. Additional class actions involve Primo Brands Corporation and Klarna Group plc with their respective deadlines.

GOOGL - Significant financial resources, notable quantum computing milestones, potential to advance AI efforts, and ability to leverage quantum computing for Google Cloud growth
JYD - Company is subject to securities class action lawsuit alleging fraudulent stock promotion schemes, insider share dumping, false statements about business operations, and materially misleading public disclosures regarding artificial trading activity and price inflation campaigns.

#securities class action #lead plaintiff deadline #fraudulent stock promotion #misleading statements #investor compensation #class action lawsuit

Johnson & Johnson Touts Encouraging Results For Experimental Lupus Treatment

Benzinga • Vandana Singh

Johnson & Johnson Touts Encouraging Results For Experimental Lupus Treatment

01/06/2026 01:42 PM • Johnson & Johnson announced positive Phase 2b results for nipocalimab, an experimental FcRn blocker for treating systemic lupus erythematosus (SLE). The JASMINE study of 228 subjects met its primary endpoint and key secondary endpoints, with a favorable safety profile. The company plans to initiate Phase 3 trials. The lupus treatment market includes competing programs from UCB/Biogen, Cartesian Therapeutics, and Adicet Bio.

JNJ - Positive Phase 2b trial results for nipocalimab meeting primary and key secondary endpoints with favorable safety profile; company advancing to Phase 3 development

#lupus treatment #nipocalimab #Phase 2b results #systemic lupus erythematosus #FcRn blocker #clinical trial #autoimmune disease

Why These 3 Mega-Caps Could Still Surprise Investors in 2026

Investing.com • Jordan Chussler

Why These 3 Mega-Caps Could Still Surprise Investors in 2026

01/06/2026 01:36 PM • The article identifies three mega-cap stocks—Visa, Walmart, and Amazon—as potential growth opportunities for 2026. Despite the market's focus on high-flying AI stocks, these companies offer steady growth with strong analyst support. Visa benefits from deregulation and crypto expansion, Walmart combines modest EPS growth with reliable dividend increases, and Amazon's heavy AI/automation investments are expected to drive future earnings growth.

V - Strong 5-year EPS growth of ~16% with analyst forecasts of 13.5% future growth. Expanding crypto-linked payment cards business grew 525% in 2025. High institutional ownership (82%), low short interest (1.37%), and 24 of 28 analysts assign Buy ratings.

#mega-cap stocks #growth investing #dividend stocks #AI investment #payment processors #e-commerce #cloud services

Can Beyond Meat Stock Bounce Back in 2026?

The Motley Fool • Will Ebiefung

Can Beyond Meat Stock Bounce Back in 2026?

01/06/2026 01:35 PM • Beyond Meat stock has plummeted 77% over the past 12 months, falling from a 2019 peak of $235 to just $0.77, entering penny stock territory. The plant-based meat company faces declining revenue, mounting losses, and waning consumer interest as the sector's initial hype fades. With a lack of growth strategy and limited addressable market beyond vegetarians/vegans, analysts rate the stock as poor investment quality with bankruptcy risks, making a sustainable rebound unlikely in 2026.

BYND - The company faces severe operational challenges including 77% stock decline over 12 months, 13.3% revenue drop in Q3, $112 million operating losses, deteriorating margins (5.98%), and declining consumer interest in plant-based meat products. The article rates investment quality as 1-2 out of 10, citing lack of growth, potential bankruptcy risk, and inability to regain market interest after the fad has passed.

#plant-based meat #consumer demand #revenue decline #operating losses #penny stock #market fad #turnaround strategy #gross margin #bankruptcy risk

Ziihera® (zanidatamab-hrii) Combinations Achieve Unprecedented Results in First-Line HER2+ Locally Advanced or Metastatic GEA including more than Two Years Median Overall Survival Benefit

GlobeNewswire Inc. • Zymeworks Inc.

Ziihera® (zanidatamab-hrii) Combinations Achieve Unprecedented Results in First-Line HER2+ Locally Advanced or Metastatic GEA including more than Two Years Median Overall Survival Benefit

01/06/2026 01:34 PM • Zymeworks announced positive Phase 3 HERIZON-GEA-01 results for Ziihera (zanidatamab-hrii) in combination with chemotherapy, with or without tislelizumab, for first-line treatment of HER2-positive gastroesophageal adenocarcinoma. The trial demonstrated statistically significant improvements in progression-free survival (approximately 35% risk reduction) and overall survival (26.4 months median, representing a 7+ month improvement over trastuzumab). Zymeworks is eligible to receive up to $440 million in milestone payments from regulatory approvals across major markets.

JEF - Mentioned as a conference host with no specific positive or negative implications
ZYME - Positive Phase 3 trial results demonstrating significant clinical benefits (7+ month OS improvement, longest reported in GEA Phase 3 trials), potential to become new standard of care, and substantial near-term milestone payments ($440M) from partners Jazz and BeOne across major markets (US, Europe, Japan, China). Results validate the company's Azymetric platform technology.

#HER2-positive gastroesophageal cancer #zanidatamab #Phase 3 trial #overall survival benefit #first-line treatment #immunotherapy combination #Azymetric platform #regulatory milestones

Global Sleep Tech Devices Market Poised for Strong Growth at a CAGR of ~17% by 2032, Driven by Rising Sleep Disorder Prevalence | DelveInsight

GlobeNewswire Inc. • Delveinsight

Global Sleep Tech Devices Market Poised for Strong Growth at a CAGR of ~17% by 2032, Driven by Rising Sleep Disorder Prevalence | DelveInsight

01/06/2026 01:00 PM • The global sleep tech devices market is expected to grow from USD 17 billion in 2024 to USD 44 billion by 2032, driven by rising sleep disorder prevalence, increased awareness, and technological advancements. Wearables dominate with 69.69% revenue share, while North America leads regional growth. Key players include Philips, ResMed, Apple, Garmin, and Eight Sleep.

RMD - Identified as a key player in the sleep tech market, which is experiencing strong growth driven by increasing adoption of home-based care and remote patient monitoring solutions.

#sleep tech devices #wearables #sleep disorders #market growth #CAGR 17% #insomnia #obstructive sleep apnea #remote patient monitoring #AI integration #smartwatches

Nombre d'actions et de droits de vote au 31 décembre 2025

GlobeNewswire Inc. • Na

Nombre d'actions et de droits de vote au 31 décembre 2025

01/06/2026 01:00 PM • Orange has signed a binding agreement with Lorca to acquire their 50% stake in MasOrange, consolidating full ownership of the joint venture. The announcement was made on December 12, 2025.

ORANY - The acquisition of Lorca's 50% stake in MasOrange represents strategic consolidation and increased control over the joint venture, which is typically viewed as a positive development for shareholder value and operational control.

#acquisition #MasOrange #joint venture #binding agreement #stake purchase

Total number of shares and voting rights at December 31, 2025

GlobeNewswire Inc. • Na

Total number of shares and voting rights at December 31, 2025

AREBW - Company is expanding distribution, meeting with numerous distributors, and successfully entering new markets with strategic partnerships
ORANY - The acquisition of Lorca's 50% stake in MasOrange represents strategic consolidation and increased control over the joint venture, which is typically viewed as a positive development for shareholder value and operational control.

#acquisition #MasOrange #joint venture #stake purchase #binding agreement

$HAREHOLDER ALERT: The M&A Class Action Firm Is Investigating the Merger—DVAX, FONR, DBRG, and ONTF

GlobeNewswire Inc. • Juan Monteverde

$HAREHOLDER ALERT: The M&A Class Action Firm Is Investigating the Merger—DVAX, FONR, DBRG, and ONTF

01/06/2026 12:56 PM • Class action law firm Monteverde & Associates PC is investigating four merger and acquisition transactions: Dynavax Technologies' sale to Sanofi ($15.50/share), FONAR Corporation's sale to affiliates of its CEO ($19.00-$6.34/share), DigitalBridge Group's sale to SoftBank ($16.00/share), and ON24's sale to Cvent Atlanta ($8.10/share). The firm is seeking shareholders to determine if the proposed deal terms are fair.

KMB - Mentioned as an offtake agreement partner for green hydrogen, indicating potential sustainability initiatives
DVAX - Under investigation by class action firm regarding sale to Sanofi, suggesting potential concerns about deal fairness or shareholder value

#class action #merger investigation #shareholder rights #M&A transaction #deal fairness

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Corcept Therapeutics Incorporated - CORT

GlobeNewswire Inc. • Pomerantz Llp

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Corcept Therapeutics Incorporated - CORT

01/06/2026 12:53 PM • Pomerantz LLP is investigating potential securities fraud claims against Corcept Therapeutics following the FDA's issuance of a Complete Response Letter for its relacorilant drug on December 31, 2025. Despite the company's pivotal GRACE trial meeting its primary endpoint, the FDA requested additional effectiveness evidence. The announcement triggered a 50.42% stock price decline, falling from $70.20 to $34.80 per share.

CORT - The company received an FDA Complete Response Letter denying approval for its lead drug candidate relacorilant, resulting in a severe 50.42% stock price decline. Additionally, securities fraud investigations have been initiated against the company and its officers/directors, indicating potential investor harm and regulatory setbacks.

#securities fraud #class action lawsuit #FDA Complete Response Letter #relacorilant #hypercortisolism #stock price decline #drug approval

The 2026 Washington, D.C. Auto Show Welcomes New Manufacturers, Returning Favorites, and Immersive Experiences

GlobeNewswire Inc. • Na

The 2026 Washington, D.C. Auto Show Welcomes New Manufacturers, Returning Favorites, and Immersive Experiences

01/06/2026 12:53 PM • The 2026 Washington, D.C. Auto Show returns to the Walter E. Washington Convention Center from January 23 to February 1, 2026, featuring new manufacturers like Harley-Davidson and VinFast alongside returning brands such as Land Rover. Major automakers including Kia, Chevrolet, Toyota, Tesla, Polestar, and Subaru will showcase their latest vehicles, with highlights including Kia's Telluride Hybrid Prototype and Polestar's electric lineup. The show will feature exclusive Ride & Drive experiences and interactive exhibits celebrating automotive innovation and sustainability.

HOG - New manufacturer entry to the show expands their market presence and visibility to D.C. automotive enthusiasts, representing growth opportunity.

#auto show #electric vehicles #automotive innovation #Ride & Drive experiences #sustainable transportation #new manufacturers #vehicle showcase

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of New Era Energy & Digital, Inc. - NUAI

GlobeNewswire Inc. • Pomerantz Llp

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of New Era Energy & Digital, Inc. - NUAI

01/06/2026 12:51 PM • Pomerantz LLP is investigating New Era Energy & Digital (NUAI) for potential securities fraud following damaging reports from short-sellers Fuzzy Panda and Hunterbrook. Fuzzy Panda alleged the company spent 2.5x more on stock promotions than operations, while Hunterbrook reported New Mexico sued the company for orchestrating a fraudulent oil-and-gas scheme. NUAI stock fell 6.9% on December 13 and another 48.03% by December 29, 2025.

NUAI - Company faces multiple serious allegations including securities fraud investigation, short-seller reports questioning business practices and CEO history, state lawsuit for fraudulent oil-and-gas scheme, and significant stock price declines (55% total over two weeks). Multiple credibility challenges and regulatory/legal issues indicate substantial investor risk.

#securities fraud #class action lawsuit #short seller report #stock price decline #oil and gas #penny stock #environmental liability

EVP and COO Sells 23,654 Innodata Shares for $1.4 Million

The Motley Fool • Will Healy

EVP and COO Sells 23,654 Innodata Shares for $1.4 Million

01/06/2026 12:30 PM • Ashok Mishra, EVP and COO of Innodata, sold 23,654 shares worth approximately $1.4 million on December 4, 2025, through an option exercise and immediate sale. This represents a 28% reduction in his direct holdings, leaving him with 60,000 shares. Despite the insider selling, analysts note this is not necessarily bearish as Mishra retained a significant position and the stock has surged from $5 in spring 2024 to over $60, driven by AI-driven data solutions.

SHOP - Mentioned only in context of CEO Kaz Nejatian's previous role as COO, with no direct analysis of the company's performance
INOD - While insider selling could be viewed negatively, the article frames this as a routine position trimming rather than a bearish signal. Mishra retained 60,000 shares, indicating continued confidence. The stock has experienced significant growth from $5 to $60+ driven by AI adoption, and the P/E ratio of ~60 is reasonable for a growth-oriented AI stock. The sale appears to be profit-taking at a favorable valuation rather than a loss of confidence in the company.

#insider selling #stock options #AI-driven solutions #data engineering #digital transformation #executive compensation #liquidity event

Bronstein, Gewirtz & Grossman LLC Urges StubHub Holdings, Inc. Investors to Act: Class Action Filed Alleging Investor Harm

GlobeNewswire Inc. • Bronstein, Gewirtz & Grossman Llc

Bronstein, Gewirtz & Grossman LLC Urges StubHub Holdings, Inc. Investors to Act: Class Action Filed Alleging Investor Harm

01/06/2026 12:00 PM • A class action lawsuit has been filed against StubHub Holdings, Inc. alleging that its September 2025 IPO registration statement was materially false and misleading. The complaint claims the company omitted disclosure of changes in vendor payment timing that significantly impacted free cash flow, and that positive statements about the company's business lacked a reasonable basis. Investors have until January 23, 2026 to request lead plaintiff status.

PLTR - 63% Q3 revenue growth, 52% government revenue increase, profitable with $393.3 million Q3 operating income, consistent sales growth
STUB - The company is accused of making materially false and misleading statements in its IPO registration statement, specifically regarding vendor payment timing changes and their impact on free cash flow. These allegations of securities fraud and disclosure violations represent significant legal and reputational risk to investors.

#class action lawsuit #securities fraud #IPO #registration statement #free cash flow #investor harm #material misstatement

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Baidu, Inc. - BIDU

GlobeNewswire Inc. • Pomerantz Llp

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Baidu, Inc. - BIDU

01/06/2026 12:00 PM • Law firm Pomerantz LLP is investigating Baidu for potential securities fraud following a Bloomberg report that the Pentagon concluded the Chinese tech company should be added to a list of firms aiding the Chinese military. Baidu's ADR stock fell 1.31% on the news.

BBAI.WS - Q3 sales fell 20%, operating losses doubled, net losses of $288 million, struggling revenue growth, and challenges maintaining government contracts
BIDU - Pentagon designation as aiding Chinese military triggered securities fraud investigation and caused immediate 1.31% stock price decline, raising concerns about regulatory risks and potential delisting or sanctions.

#securities fraud #Pentagon #Chinese military #class action #stock decline

Bronstein, Gewirtz & Grossman LLC Urges SLM Corporation a/k/a Sallie Mae Investors to Act: Class Action Filed Alleging Investor Harm

GlobeNewswire Inc. • Bronstein, Gewirtz & Grossman Llc

Bronstein, Gewirtz & Grossman LLC Urges SLM Corporation a/k/a Sallie Mae Investors to Act: Class Action Filed Alleging Investor Harm

01/06/2026 12:00 PM • A class action lawsuit has been filed against SLM Corporation (Sallie Mae) alleging that the company made materially false and misleading statements regarding its business operations. The complaint claims defendants overstated the effectiveness of loss mitigation programs and concealed a significant increase in early-stage loan delinquencies, artificially inflating stock prices during the July 25 - August 14, 2025 period. Investors have until February 17, 2026 to request lead plaintiff status.

SLM - The company is accused of making materially false and misleading statements about its business operations, specifically concealing significant increases in early-stage delinquencies and overstating the effectiveness of its loss mitigation programs. These allegations of securities fraud and investor harm directly harm shareholder value and company reputation.

#class action lawsuit #securities fraud #false statements #loan delinquencies #investor harm #lead plaintiff deadline

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Ventyx Biosciences, Inc. - VTYX

GlobeNewswire Inc. • Pomerantz Llp

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Ventyx Biosciences, Inc. - VTYX

01/06/2026 12:00 PM • Pomerantz LLP is investigating potential securities fraud claims against Ventyx Biosciences following the company's December 2, 2025 announcement that it was delaying topline data release from its Phase 2 recurrent pericarditis trial to Q1 2026. The delay announcement triggered a 15.35% stock price decline, falling from approximately $9.38 to $7.94 per share.

NVDA - Earnings results anticipated this week, with market watching closely
VTYX - The company faces a securities fraud investigation following a significant stock price decline (15.35%) triggered by the announcement of a clinical trial data delay. The delay and subsequent investigation suggest potential investor concerns about misleading guidance or undisclosed material information.

#securities fraud #class action lawsuit #clinical trial delay #stock price decline #Phase 2 study #VTX2735

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Village Farms International, Inc. - VFF

GlobeNewswire Inc. • Pomerantz Llp

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Village Farms International, Inc. - VFF

01/06/2026 12:00 PM • Pomerantz LLP is investigating potential securities fraud claims against Village Farms International following the company's failure to secure a conditional medical license from the Texas Department of Public Safety on December 1, 2025. The announcement triggered a 9.3% stock price decline on December 2, 2025.

PLTR - Advanced 0.73% after partnering with Multiverse to launch NHS staff apprenticeship programs
VFF - The company failed to obtain a conditional medical license from Texas DPS, resulting in a 9.3% stock price drop. Additionally, a law firm is investigating potential securities fraud and unlawful business practices by company officers and/or directors, indicating serious legal and operational challenges.

#securities fraud #class action lawsuit #Village Farms International #Texas medical license #stock price decline #investor investigation

PRMB INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Primo Brands Corporation Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit

GlobeNewswire Inc. • Bronstein, Gewirtz & Grossman Llc

PRMB INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Primo Brands Corporation Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit

01/06/2026 12:00 PM • A class action lawsuit has been filed against Primo Brands Corporation and its officers for alleged securities law violations. The complaint alleges that defendants misrepresented facts about the merger between Primo Water and BlueTriton Brands, making false statements about merger integration progress, growth acceleration, operational efficiencies, and synergies. Investors who purchased stock during the specified periods are encouraged to join the case, with a lead plaintiff deadline of January 12, 2026.

BApA - Slight 0.30% increase after Emirates placed third order for 777X airplanes
PRMB - Company is subject to a class action lawsuit alleging securities fraud, misrepresentation of merger integration progress, and false statements about financial performance and synergies, resulting in investor losses.

#class action lawsuit #securities fraud #merger integration #misrepresentation #investor losses #Primo Water #BlueTriton Brands

Bronstein, Gewirtz & Grossman LLC Urges Stride, Inc. Investors to Act: Class Action Filed Alleging Investor Harm

GlobeNewswire Inc. • Bronstein, Gewirtz & Grossman Llc

Bronstein, Gewirtz & Grossman LLC Urges Stride, Inc. Investors to Act: Class Action Filed Alleging Investor Harm

01/06/2026 12:00 PM • A class action lawsuit has been filed against Stride, Inc. alleging securities fraud during the period of October 22, 2024 to October 28, 2025. The complaint claims Stride made misleading statements about its educational products and services while allegedly inflating enrollment numbers with 'ghost students,' violating staffing requirements, ignoring compliance and special education mandates, suppressing whistleblowers, and losing enrollments to preserve profit margins.

BA - Slight 0.30% increase after Emirates placed third order for 777X airplanes
LRN - The company is accused of multiple serious violations including fraudulent enrollment practices, staffing violations, regulatory non-compliance, special education service denials, and whistleblower suppression. These allegations represent significant operational, legal, and reputational risks that would negatively impact investor confidence and shareholder value.

#class action lawsuit #securities fraud #Stride Inc. #investor harm #misleading statements #ghost students #enrollment inflation #compliance violations #whistleblower suppression